8:10 AM
 | 
Feb 09, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Madrigal reports Phase II data of MGL-3196 for HeFH

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) reported Phase II data for MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH) that, despite meeting the primary endpoint, suggest the candidate would be unable to compete with marketed drugs in the indication.

Madrigal said MGL-3196 led to significant placebo-adjusted reductions in LDL-C from baseline to week 12, the primary endpoint, of 18.8% in all patients, 21% in patients who received the optimal dosing regimen of MGL-3196 and 28.5% in a prespecified subgroup of...

Read the full 366 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >